Prognostic and Predictive Value of Hematologic Parameters in Patients with Metastatic Renal Cell Carcinoma: Second Line Sunitinib Treatment Following IFN-alpha

• DOI: 10.7314/apjcp.2013.14.3.2101
• Publication Date: 2013-08-08T05:33:45Z
• Authors: Ahmet Dirican; Yuksel Kucukzeybek; Cigdem Erten; Isil Somali; Lutfiye Demir; Alper Can; Kadriye Bahriye P...; Ibrahim Vedat Bay...; Murat Akyol; Yasar Yildiz; Mehmet Koseoglu; Ahmet Alacacioglu; Mustafa Oktay Tarhan
• Keywords: Sunitinib malate

Long-term survival is a problem with locally advanced and metastatic renal cell carcinomas. Sunitinib malate an oral multitargeted tyrosine kinase inhibitor, but data on sunitinib use as second line treatment in carcinoma (mRCC) are limited. Prognostic predictive value of peripheral blood markers has been shown for many cancers.Efficacy safety profiles after interferon alpha were evaluated based retrospective 23 patients mRCC. Hematological parameters (neutrophils, lymphocytes, platelets, mean platelet volume, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio) recorded at the time metastasis. It was whether hematological prognostic factors.Median progression-free (PFS) 16.5 months (95%CI: 0-34.5). Median overall (OS) 25.7 10.8-40.0). Most common side effects neutropenia (52.2%), stomatitis (26.1%) hand-food syndrome (26.1%). PFS found 3.13 vs 17.1 neutrophil / lymphocyte ratio (NLR)>3 NLR≤3 (p:0.012). OS 6.96 27.1 NLR>3 (p:0.001).While 75% who responded to had NLR≤3, 72% no response detected (p:0.036). The association between Memorial Sloan-Kettering Cancer Center (MSKCC) criteria NLR statistically significant (p:0.022).Data following cytokine mRCC In our study, we observed IFN-alpha be effective tolerable. appeared have value.